Levetiracetam 1a Farma

Levetiracetam, the active ingredient in Levetiracetam 1a Farma, is an antiepileptic presented as an intravenous solution for intravenous use. It is employed to control partial seizures, generalized tonic‑clonic seizures and other seizure types in patients who require parenteral therapy, providing rapid plasma concentrations.

GNH USA supplies Levetiracetam 1a Farma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, and healthcare providers in both developed and emerging markets.

Levetiracetam is an antiepileptic medication used to manage seizure disorders.

Partial seizures: decreases the number and intensity of focal onset seizures, improving patient stability. Generalized tonic‑clonic seizures: assists in controlling convulsive episodes in generalized epilepsy, reducing seizure‑related injury. Epilepsy (overall): serves as adjunctive therapy for multiple seizure types, especially when rapid intravenous administration is required. Refractory seizures: provides an additional option for patients whose seizures are not controlled by first‑line agents.

Levetiracetam may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness: transient sensation of lightheadedness that may affect balance. - Fatigue: feeling unusually tired or weak during treatment. - Headache: mild to moderate head pain that can occur intermittently. - Nausea: upset stomach or urge to vomit, often transient.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing requiring immediate medical attention. - Psychiatric symptoms: new or worsening depression, anxiety, or suicidal thoughts. - Blood disorders: rare cases of thrombocytopenia or leukopenia. - Multiorgan hypersensitivity: systemic reaction with fever, eosinophilia, and organ involvement.

When using Levetiracetam, several precautions should be observed to ensure safe administration. - Renal function: adjust dose in patients with impaired kidney function, as the drug is primarily excreted unchanged. - Pregnancy: limited data; use only if potential benefit justifies potential risk to the fetus. - Psychiatric monitoring: observe for mood changes, depression, or suicidal ideation during therapy. - Concomitant CNS depressants: use caution when combined with other central nervous system depressants, as additive sedation may occur. - Drug interactions: review patient medication list for potential interactions, especially with enzyme‑inducing antiepileptics. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Enzyme‑inducing antiepileptics (e.g., carbamazepine, phenytoin): may reduce levetiracetam plasma levels, decreasing effectiveness. - Strong CYP450 inhibitors: may increase levels of co‑administered drugs, requiring toxicity monitoring.

Moderate Interactions (Monitor Closely): - Sedatives or alcohol: may enhance central nervous system depression, leading to increased drowsiness. - Anticoagulants (e.g., warfarin): levetiracetam may alter INR; monitor coagulation parameters. - Oral contraceptives: possible reduction in efficacy; advise alternative contraception.